UROGEN PHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.15 USD | +2.39% |
|
+3.06% | -5.67% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -5.67% | 483M | B- | ||
| -2.31% | 103B | B+ | ||
| +0.56% | 95.28B | B+ | ||
| +0.90% | 22.15B | B | ||
| -17.37% | 21.02B | B+ | ||
| -8.31% | 18.15B | A- | ||
| -41.01% | 16.73B | A- | ||
| -14.85% | 16.05B | B | ||
| +3.21% | 13.68B | C+ | ||
| +33.54% | 12.17B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- URGN Stock
- Ratings UroGen Pharma Ltd.
